Life Science Litigation Practice Chair and Patent Litigation Practice Co-chair Sige Gutman recently spoke with Life Sciences Intellectual Property Review about the latest federal developments impacting the US Patent and Trademark Office, including hiring freezes, layoffs, the elimination of non-essential functions, and a return-to-office directive. The article analyzes the potential implications of the changes, particularly for pharma and biotech companies, as patent pendency times are already increasing due to a high volume of recent applications.

Sige commented that "If you know what the rules of the game are, you can develop strategies and ways to address change and uncertainty."

Source

Life Sciences Intellectual Property Review